The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma.
暂无分享,去创建一个
J. Shuster | A. Cantor | R. Marcus | F. A. Hayes | R. Castleberry | E. I. Smith | N. Mcwilliams | J. Pole | T. Pick
[1] J. Shuster,et al. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Love,et al. IS HIGH-DOSE MELPHALAN (HDM) OF VALUE IN TREATMENT OF ADVANCED NEUROBLASTOMA (AN) - PRELIMINARY-RESULTS OF A RANDOMIZED TRIAL BY THE EUROPEAN NEUROBLASTOMA STUDY-GROUP (ENSG) , 1987 .
[3] S. Feig,et al. Metastatic neuroblastoma managed by supralethal therapy and bone marrow reconstitution (BMRc). Results of a four-institution Children's Cancer Study Group pilot study. , 1985, Progress in clinical and biological research.
[4] D. Rogers,et al. Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Evans,et al. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Graham-Pole,et al. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. , 1982, British Journal of Cancer.
[7] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[8] Nathan Mantel,et al. Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data , 1974 .
[9] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .